NASDAQ : SPRO

Spero Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 1.06 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 61.73M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Details

NameSpero Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees25
Founded2013
Ipo Date2017-11-02
CeoEsther Rajavelu
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS84833T1034
Cusip84833T103
Cik0001701108
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Esther P. RajaveluChief Executive Officer, President, Chief Financial Officer, Chief Business Officer, Treasurer and Director
Timothy KeutzerChief Operating Officer
John RaymondSenior Vice President of Finance and Business Operations
Dr. Debra Jeske Zack M.D., Ph.D.Chief Medical Officer

Contact

Address675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139, United States
Phone857 242 1600
Websitehttps://sperotherapeutics.com